Median Effective Dose of Esketamine Pretreatment to Prevent Sufentanil-induced Cough
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Sufentanil has the advantages of fast onset time, strong analgesic function and
cardiovascular stability, and is widely used during general anesthesia induction. However,
sufentanil can cause cough during induction of general anesthesia. Different studies have
reported that the incidence of sufentanil-induced cough ( SIC ) during anesthesia is 16-42 %.
This pathological condition may lead to damage to the central nervous system, increase the
risk of reflux and aspiration, increase intracranial pressure and intraocular pressure, and
endanger patients with cerebral aneurysms and ocular trauma. Therefore, at the moment of
advocating comfortable anesthesia medical services, sufentanil-induced cough response is a
problem that clinical anesthesiologists need to focus on and urgently solve. It has been
reported that ketamine can reduce the incidence of cough caused by opioids. Esketamine is a
pure dextro-enantiomer of ketamine and an NMDA antagonist with potent analgesic and
bronchodilator effects. In this study, Dixon sequential method was used to study the median
effective dose ( ED50 ) of intravenous esketamine pretreatment to prevent sufentanil-induced
cough, and to explore the effect of age on ED50. To provide reference for clinical rational
selection of esketamine dose.